Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL242 + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- MediLink Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YL242 + 5-fluorouracil + leucovorin is a combination therapy regimen being evaluated for the treatment of various advanced solid tumors. YL242 is an antibody-drug conjugate (ADC) developed by MediLink Therapeutics using its proprietary TMALIN (Tumor Microenvironment Activable LINker-payload) technology. It targets Vascular Endothelial Growth Factor (VEGF) and consists of an anti-VEGF antibody conjugated to a novel DNA topoisomerase I inhibitor payload via a protease-cleavable tripeptide linker. The combination includes 5-fluorouracil (5-FU), a pyrimidine analog antimetabolite that inhibits thymidylate synthase and incorporates into RNA and DNA, and leucovorin (LV), which stabilizes the binding of 5-FU to its target. This therapeutic approach combines anti-angiogenic effects and targeted cytotoxic delivery from the ADC with the established chemotherapeutic activity of the 5-FU/LV backbone to treat cancers such as colorectal, gastric, and non-small cell lung cancer.
- Other names
- YL242 + 5-FU + LVYL242 + fluorouracil + leucovorin
02
Targets
Beyond the preview
Go deeper on YL242 + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL242 + 5-fluorouracil + leucovorin.